Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lutetium (177Lu) oxodotreotide versus long-acting octreotide in progressive, unresectable or metastatic SSTR-positive GEP-NETs
CTR20221314Phase 3Active
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Sep 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Sinotau Pharmaceutical Group. Started Sep 2022; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20221314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221314.